Overview

A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

Status:
Terminated

Trial end date:
2015-04-24

Target enrollment:

Participant gender:

Summary

Study AMAG-FER-CKD-253 is an extension study of the combined AMAG-FER-CKD-251 (NCT01155375) and AMAG-FER-CKD-252 (NCT01155388) studies to evaluate the efficacy and safety of episodic treatment of iron deficiency anemia (IDA) with ferumoxytol.

Phase:

Phase 3

Details

Lead Sponsor:

AMAG Pharmaceuticals, Inc.

Treatments:

Ferrosoferric Oxide